Why the study?
Does administering IPV prior to OPV reduce vaccine-associated poliomyelitis?
Does administering IPV prior to OPV reduce vaccine-associated poliomyelitis?
Answers are grounded in this paper and cite their sources.
While IPV prior to OPV may protect the recipient, its ability to prevent vaccine-associated poliomyelitis in contacts is limited by variable effects on fecal viral excretion.
In Reply.— Drs Eggers and Mertens raise an important issue: Can even the small number of cases of poliomyelitis associated with oral poliomyelitis vaccine (OPV) be reduced by administering inactivated poliomyelitis vaccine (IPV) prior to OPV administration? Theoretically, induction of individual immunity by IPV should prevent recipient cases of vaccine-associated poliomyelitis. In support of this argument, two doses of an IPV with enhanced potency were found to bring about triple seroconversion in over 97% of recipients.1Nonetheless, approximately 60% of current vaccine-associated poliomyelitis cases occur in contacts of OPV recipients. Although IPV of current potency has been shown to reduce pharyngeal shedding of OPV virus following challenge, the effect on subsequent fecal excretion of OPV virus is variable and of unknown epidemiologic significance2-4; the effect of an enhanced-potency product is apparently also limited (I. M. Onorato, MD, written communication, April 1987). There are also potential problems with combined
No takes yet. Share an insight, caveat, or question.
Steven G. F. Wassilak (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: